KKKaan Kumru

Kaan Kumru

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kaan Kumru has a total of 47 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    ACKR3 Establishes a Squamous-Restricted Immune Checkpoint Axis in Lung Squamous Cell Carcinoma

    by Angeliki Karatza, Kaan Kumru, Jaylen M. Powell, Chengwei Peng, Yuan Hao, Metamia Ciampricotti, Dimitris Nasias, Hai Hu, Muhammad Elnaggar, Maayan Pour, et al.

    Lung squamous cell carcinoma (LUSC) is an aggressive subtype of non–small cell lung cancer (NSCLC) with limited targeted therapeutic options and incompletely defined immunoregulatory dependencies. In this study, we identified atypical chemokine receptor 3 (ACKR3) as a squamous-enriched regulator that restrains malignant progression in LUSC. Integrative analyses of human LUSC datasets, autochthonous genetically engineered mouse models (GEMM), and ex vivo organoid systems showed that ACKR3 loss accelerated tumor growth and remodeled the immune microenvironment, marked by reduced CD8+ T-cell infiltration and increased T-cell exhaustion. Mechanistically, ACKR3 limited the activation of the macrophage migration inhibitory factor (MIF)–CD74–PD-L1 axis, thereby constraining tumor-cell PD-L1 expression and preserving antitumor immune surveillance. In preclinical LUSC models, treatment with the ACKR3-directed PD-L1 degrader, cytokine receptor–targeting chimera (KineTAC), a bispecific molecule that coengages ACKR3 and PD-L1 to promote lysosomal degradation of PD-L1, enhanced antitumor efficacy, particularly in combination with chemotherapy. Together, these findings define ACKR3 as a squamous-associated immune checkpoint regulator and nominate ACKR3-directed PD-L1 degradation as a tumor-selective therapeutic strategy for LUSC. Significance: ACKR3 is a lineage-imprinted checkpoint restraining MIF–CD74–driven PD-L1 induction in lung squamous cell carcinoma that can be harnessed for PD-L1 degradation to induce tumor-restricted checkpoint dismantling.

  • Open Access

    A cytokine receptor-targeting chimera (kineTAC) toolbox for expanding extracellular targeted protein degradation

    by Kaan Kumru, Zi Yao, Brandon B. Holmes, Fangzhu Zhao, Yun Zhang, Emilio Ferrara, Trenton M. Peters-Clarke, Kevin K. Leung, James A. Wells

    Extracellular targeted protein degradation (eTPD) is as an important new modality for manipulating the extracellular proteome. However, most eTPD receptors are expressed broadly or are restricted to the liver. Cytokine receptor targeting chimeras (kineTACs) are genetically encoded bispecifics for eTPD that fuse a natural ligand like CXCL12 to an antibody, directing soluble or membrane proteins for lysosomal degradation using the widely expressed chemokine receptor CXCR7 (Pance K, Gramespacher JA., Byrnes, JR, Salangsang F., Serrano JAC, Cotton AD, Steri V, and Wells JA, Nat. Biotechnol . 2023 , 41, 273-281). Here, we dramatically expand the kineTAC toolbox by constructing 81 new kineTACs based on an unbiased list of cytokines, chemokines and growth factors. Remarkably, 55 of these expressed at suitable levels for analysis without any optimization. Many of these kineTACs bind receptors that have unique cell-type expression profiles, allowing for eTPD in specific cells and tissues and some were more potent than the original CXCL12-based kineTAC. We further show the internalizing capability of a kineTAC can enhance the performance of antibody drug conjugates. We believe these simple, genetically encoded tools will be useful for expanding the applications for optimized or cell type-selective eTPD.


  • Open Access

    Insights into modular polyketide synthase loops aided by repetitive sequences

    by Melissa Hirsch, Kaan Kumru, Ronak R. Desai, Brendan J. Fitzgerald, Takeshi Miyazawa, Katherine A. Ray, Nisha Saif, Samantha Spears, Adrian T. Keatinge‐Clay

    The loops of modular polyketide synthases (PKSs) serve diverse functions but are largely uncharacterized. They frequently contain amino acid repeats resulting from genetic events such as slipped‐strand mispairing. Determining the tolerance of loops to amino acid changes would aid in understanding and engineering these multidomain molecule factories. Here, tandem repeats in the DNA encoding 949 modules within 129 cis‐acyltransferase PKSs were cataloged, and the locations of the corresponding amino acids within the module were identified. The most frequently inserted interdomain loop corresponds with the updated module boundary immediately downstream of the ketosynthase (KS), while the loops bordering the dehydratase are nearly intolerant to such insertions. From the 949 modules, no repetitive sequence loop insertions are located within ACP, and only 2 reside within KS, indicating the sensitivity of these domains to alteration.


  • General chemoenzymatic route to two-stereocenter triketides employing assembly line ketoreductases

    by Zhicheng Zhang, Alexis J. Cepeda, Mireya L. Robles, Melissa Hirsch, Kaan Kumru, Jina A. Zhou, Adrian T. Keatinge-Clay

    Modular polyketide synthases (PKSs) are enzymatic assembly lines that fuse carbon fragments into complex chiral products. Here, their synthetic logic is employed to chemoenzymatically generate two-stereocenter triketides. Each of the four stereoisomers was constructed in a stereocontrolled manner using C-acylation and two PKS ketoreductases possessing opposite stereoselectivities.